SAGE Therapeutics (SAGE) Misses Q2 EPS by 21c

SAGE Therapeutics (NASDAQ: SAGE) reported Q2 EPS of ($1.88), $0.21 worse than the analyst estimate of ($1.67).

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• Evercore lifts Ciena rating on AI-driven optical networking boom
• Lennar Corp. (LEN) Misses Q3 EPS by 10c